{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.8","upperLimit":"264.1","value":"150.8"},{"groupId":"OG001","lowerLimit":"145.1","upperLimit":"357.7","value":"239.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"361"}],"units":"Participants"}],"description":"Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer?","dispersionType":"Inter-Quartile Range","groups":[{"description":"prostate adenocarcinoma in pathologic evaluation","id":"OG000","title":"Prostate Cancer"},{"description":"benign prostatic diseases in pathologic evaluation","id":"OG001","title":"Control"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks","title":"Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases","type":"PRIMARY","unitOfMeasure":"ratio"}